Sumitomo Chemical started its pharmaceuticals business as the first Japanese company to manufacture synthetic pharmaceuticals based on its advanced organic synthesis technology. At present, the company is developing the Sector through Sumitomo Dainippon Pharma Co., Ltd., engaged in the prescription pharmaceuticals business, and Nihon Medi-Physics Co., Ltd., engaged in the diagnostic pharmaceuticals business.
Sumitomo Dainippon Pharma Co., Ltd.
Sumitomo Dainippon Pharma focuses on the areas of cardiovascular/diabetes, diabetes, and psychiatry & neurology, as well as specialty areas such as cancer, infectious disease, and orphan disease treatments, where patients' needs are highly specialized and largely unmet. Sumitomo Dainippon Pharma markets AIMIX® (therapeutic agent for hypertension), LONASEN® (atypical antipsychotic agent), TRERIEF® (therapeutic agent for Parkinson's disease) and Trulicity® (GLP-1 receptor agonist). The company has actively taken initiatives to expand its business overseas, and in the United States, it launched LATUDA® (atypical antipsychotic agent) in 2011 through Sunovion Pharmaceuticals, which became a subsidiary in 2009. Also, in 2012, it acquired Boston Biomedical, the U.S. biotechnology venture company which specializes in the field of cancer research and development, to concentrate its R&D efforts on this area in addition to its focus area of psychiatry & neurology.
Nihon Medi-Physics Co., Ltd.
Nihon Medi-Physics is the leading company in the highly specialized field of nuclear medicine in both diagnosis and therapy. It offers a comprehensive range of functions from research and development to production, marketing and sales of radiopharmaceuticals used in diagnostic imaging procedures, such as SPECT for cerebral vascular disorder, dementia, cardiac disease, and malignant tumor, as well as PET, which is considered useful for early detection of malignant tumors. In the therapy field, it provides a radioactive seed for brachytherapy, a radiopharmaceutical product to palliate the pain caused by bone metastasis of cancers. In 2014, in order to meet increased medical needs, it launched a new diagnostic agent, "DaTSCAN® injectable," for diagnosis of Parkinson's disease and dementia with Lewy bodies. Moreover, by leveraging the experience and know-how cultivated in the manufacturing and distribution of radiopharmaceuticals, we recently diversified into contract businesses to promote the PET imaging procedure as a drug development tool in both non-clinical and clinical stages.